Glass/barrel + high-value containment + assembly. GLP-1/incretin exposure ~21-22% of revenue. Converting underutilized vial line to cartridges to bridge shortage; Fishers/Latina lines not commercial until late 2026.
Research snapshot · Not reviewed
STVNStevanato Group
Glass/barrel + high-value containment
Open STVN in Robinhood ↗Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap5.19BSnapshot value
GLP-1 demand driving high-value solutions (+31% in Q1 2026); cartridge line conversion bridging near-term shortage; Fishers (Indiana) + Latina (Italy) capacity coming late 2026/early 2027; Annex 1 RTU conversion tailwind.
GLP-1 concentration (~21-22% of revenue — swing factor); oral GLP-1 bypassing sterile bottleneck; Engineering-segment lumpiness; new-facility depreciation; capacity overbuild risk.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟡 Mixed · ins-$0.1M · 13F 11+/13- · short↑0.14
Snapshot · Not reviewed